Spinal Muscular Atrophy Market Research report and Insights 2023


Posted January 13, 2016 by MRRSE16

Based on the age of onset and symptoms, spinal muscular atrophy has been classified in four main types: type 1, type 2, type 3, and type 4, and thus the respective markets.

 
Report Description

Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness analysis considers various factors such as patient population, drug pricing policies, regulatory restrictions, current competition intensity, and current state of healthcare sector for assessing the potential of each geographical market.

In the pipeline analysis of spinal muscular atrophy (SMA) market report, market analysis and forecast has been provided for late stage (phase 3) candidates, while also includes thorough qualitative information for other candidates in early stage (phase 1 and phase 2). ISIS-SMNRx by Isis Pharmaceuticals is presently the only late stage candidate in spinal muscular atrophy pipeline, while three drugs are currently in phase 2 and three others in phase 1. These include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039.

Complete Report with TOC @ http://www.mrrse.com/spinal-muscular-atrophy-market

Scope

It has three drugs in phase 1, three in phase 2, and one in phase 3 clinical trials. ISIS-SMNRx, an antisense therapy candidate by Isis Pharmaceuticals, is currently under phase 3 studies for treatment of type 1 and 2 SMA. If approved, ISIS-SMNRx would be the only drug available of the treatment of spinal muscular atrophy, creating lucrative opportunity for Isis Pharmaceuticals and Biogen Idec. Phase 3 study is expected to complete in June 2017. The drug is projected to record sales of USD 468.2 million in the U.S. by 2023.

Key Players

Key players with potential therapeutics in clinical trial phase include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc.

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/1417

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact
Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By mrrse
Country United States
Categories Business
Tags Spinal Muscular Atrophy Market , Spinal Muscular Atrophy , Spinal Muscular Atrophy Market growth
Last Updated January 13, 2016